ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) will report fourth quarter and full year 2025 results on March 10, 2026 via a conference call and live webcast at 8:30 a.m. EDT. The call will include financial results for the period ended December 31, 2025, and operational updates.

Investors may register in advance; a participant toll-free dial-in for North America and Canada is provided and the webcast archive will be available for 30 days.

News Market Reaction – ADCT

-3.11%

13 alerts

-3.11% Session close to close

+3.5% Peak in 39 min

$546.30M Market Cap

1.5x Rel. Volume

In the Mar 3 session, ADCT declined 3.11%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.5% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing for ADCT’s fourth quarter and full-year 2025 results call on March...

Analysis

This announcement sets the timing for ADCT’s fourth quarter and full-year 2025 results call on March 10, 2026 at 8:30 a.m. EDT, with access via webcast and a 30-day replay. It continues the company’s regular pattern of quarterly earnings communications. Investors may focus on how the reported figures compare with prior preliminary 2025 updates and on any commentary around cash runway and clinical milestones discussed during the call.

Key Figures

Earnings call date: March 10, 2026 Call time: 8:30 a.m. EDT Webcast archive period: 30 days +1 more

4 metrics

Earnings call date March 10, 2026 Q4 and full-year 2025 results conference call

Call time 8:30 a.m. EDT Start time for results call and webcast

Webcast archive period 30 days Duration archived webcast remains available after call

Toll-free dial-in 1-800-836-8184 North America and Canada participant number

Previous Conferences,earnings Reports

5 past events · Latest: Nov 03 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 03	Q3 2025 call date	Neutral	-6.3%	Announced timing and access details for Q3 2025 earnings call.
Nov 03	Q3 2025 call date	Neutral	-6.3%	Repeat notice of Q3 2025 financial results conference call scheduling.
Aug 05	Q2 2025 call date	Neutral	-4.3%	Set Q2 2025 earnings call and webcast details for investors.
May 08	Q1 2025 call date	Neutral	+0.8%	Announced schedule and access info for Q1 2025 results call.
Mar 20	FY 2024 call date	Neutral	-6.6%	Scheduled Q4 and full-year 2024 financial results conference call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Scheduling earnings calls has historically coincided with modestly negative next-day moves, with an average reaction around -4% to -6% on similar announcements.

Recent Company History

Recent news for ADC Therapeutics has focused on capital structure, preliminary 2025 results, and ongoing investor communication. In Q1 2026, the company highlighted preliminary 2025 revenue and cash along with key LOTIS clinical catalysts. Through 2025, it consistently announced quarterly earnings calls around set dates with standard dial-in and webcast details. Today’s announcement continues that pattern, setting expectations for the full-year 2025 results call and operational updates.

Key Terms

antibody drug conjugates

1 terms

antibody drug conjugates medical

"a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs)"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, March 10, 2026, at 8:30 a.m. EDT to report financial results for the fourth quarter and full year ended December 31, 2025, and provide operational updates.

To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).

ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: changes to the preliminary unaudited Q4 and full year 2025 net product revenue and cash and cash equivalents as of December 31, 2025; expected cash runway at least to 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented by the Company on December 3, 2025, the timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission and full FDA approval; the Company's ability to grow ZYNLONTA^® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA^® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA^® in foreign jurisdictions; the timing and results of the Company's clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-host-fourth-quarter-and-full-year-2025-financial-results-conference-call-on-march-10-2026-302698557.html

SOURCE ADC Therapeutics SA

FAQ

When will ADC Therapeutics (ADCT) release Q4 and full year 2025 results?

ADC Therapeutics will release Q4 and full year 2025 results on March 10, 2026 at 8:30 a.m. EDT. According to the company, the call covers results for the period ended December 31, 2025 and includes operational updates and commentary from management.

How can investors attend the ADC Therapeutics (ADCT) March 10, 2026 earnings call?

Investors can attend by registering for the conference call or joining the live webcast on the investor site. According to the company, pre-registration is available and a North America toll-free number is provided for participants.

Where will the ADC Therapeutics (ADCT) March 10, 2026 webcast be hosted?

The webcast will be hosted in the Investors section under Events and Presentations on the company website. According to the company, the archived webcast will remain available for 30 days after the call for later review.

What time should I join the ADC Therapeutics (ADCT) earnings call on March 10, 2026?

The call begins at 8:30 a.m. EDT and attendees are recommended to join 10 minutes early. According to the company, joining early helps with registration and audio setup before the presentation starts.

What topics will ADC Therapeutics (ADCT) cover during the March 10, 2026 call?

The company will report financial results for Q4 and full year 2025 and provide operational updates during the call. According to the company, management commentary and performance for the period ended December 31, 2025 will be discussed.

Will ADC Therapeutics (ADCT) provide a replay of the March 10, 2026 earnings webcast?

Yes, a replay will be available for 30 days following the call on the investor website. According to the company, the archived webcast can be accessed under Events and Presentations for those who cannot join live.